Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Clinical Trial of a Q GRFT Nasal Spray

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05180500
Recruitment Status : Not yet recruiting
First Posted : January 6, 2022
Last Update Posted : January 6, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sharon Hillier, University of Pittsburgh

Brief Summary:
This is a phase I randomized, placebo-controlled, single site to assess the local and systemic safety of intranasal Q-Griffithsin (Q-GRFT) after 14 doses in approximately 45 adult participants. Participants will be randomized 2:1 (Q-GRFT nasal spray: placebo nasal spray) resulting in 30 participants enrolled into the Q-GRFT arm and 15 participants enrolled into the placebo arm. A clinician will apply two metered doses of Q-GRFT in each nostril (400μl total) of the participant on the day of enrollment. Participants will be monitored in the clinic for 1 hour after administration and return for a 24-hour post dose visit. If safe and acceptable, a second period of daily administration by the participant for 13 days will commence. Safety assessments will be performed at day 7, day 14, and day 28 visits after the initiation of the second period. The expected duration of study participation for each participant will be approximately 6-8 weeks. The primary endpoint is the proportion of participants who experience a related Grade 2 or higher adverse event. Secondary and exploratory endpoints include persistence and systemic absorption of Q-GRFT, acceptability and the impact of Q-GRFT nasal spray on smell.

Condition or disease Intervention/treatment Phase
COVID-19 Pharmacokinetics Safety Drug: Q-Griffithsin Drug: Placebo Phase 1

Detailed Description:
This is a phase 1 study for intranasal application of Q-Griffithsin (Q-GRFT) spray as a prophylactic for SARS-CoV-2. This randomized, placebo-controlled, single site will assess the local and systemic safety of intranasal Q-GRFT after 14 doses in approximately 45 adult participants. Participants will be randomized 2:1 (Q-GRFT nasal spray: placebo nasal spray) resulting in 30 participants enrolled into the Q-GRFT arm and 15 participants enrolled into the placebo arm. Accrual of approximately 45 evaluable participants is expected to take 6 months. The expected duration of study participation for each participant will be approximately 6-8 weeks. A clinician will apply two metered doses of Q-GRFT in each nostril (400μl total) of the participant on the day of enrollment. Participants will be monitored in the clinic for 1 hour after administration and return for a 24-hour post dose visit. If safe and acceptable, a second period of daily administration by the participant for 13 days will commence after a 5-49 day washout period. Safety assessments will be performed at day 7, day 14, and day 28 visits after the initiation of the second period. Additional safety assessments will be done by contacting participants between the 24-hour and 7-day visits and 7- and 14-day visits. The expected duration of study participation for each participant will be approximately 6-8 weeks. The primary endpoint is the proportion of participants who experience a related Grade 2 or higher adverse event. Secondary and exploratory endpoints include persistence and systemic absorption of Q-GRFT, acceptability and the impact of Q-GRFT nasal spray on smell.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Phase 1 Clinical Trial of a Q GRFT Nasal Spray
Estimated Study Start Date : February 1, 2022
Estimated Primary Completion Date : February 1, 2023
Estimated Study Completion Date : August 1, 2023

Arm Intervention/treatment
Active Comparator: Q-GRFT Nasal Spray
Q-Griffithsin (Q-GRFT) nasal spray (7.5mg/mL). Two metered doses of 100μL into each nostril, total of 3mg Q-GRFT per administration, administered once daily for 14 consecutive days.
Drug: Q-Griffithsin
Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.

Placebo Comparator: Placebo Nasal Spray
Placebo Nasal Spray. Two metered doses of 100μL into each nostril, administered once daily for 14 consecutive days.
Drug: Placebo
A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.




Primary Outcome Measures :
  1. Number of Participants with Related Grade 2 or Higher Adverse Events [ Time Frame: Approximately 8 weeks ]
    Number of participants with Grade 2 or higher adverse events deemed related to study product


Secondary Outcome Measures :
  1. Q-GRFT Concentration from Nasopharyngeal Swab Eluent Collected at 24 Hours [ Time Frame: Approximately 24 hours ]
    Q-GRFT concentration from nasopharyngeal swab eluent collected 24 hours after intranasal application of a single dose of study product

  2. Q-GRFT Plasma Concentration Collected at 24 Hours [ Time Frame: Approximately 24 hours ]
    Q-GRFT concentration in plasma collected 24 hours after intranasal application of a single dose of study product

  3. Area Under the Nasopharyngeal Swab Eluent Concentration versus Time Curve of Q-GRFT [ Time Frame: Approximately 28 days ]
    Area under the nasopharyngeal swab eluent concentration versus time curve of Q-GRFT collected after 13 consecutive daily intranasal applications of study product. Q-GRFT concentrations will be measured prior to the first application of study product and at 7-days, 14-days, and 28-days after the first of thirteen applications of study product.

  4. Area Under the Plasma Concentration versus Time Curve of Q-GRFT [ Time Frame: Approximately 28 days ]
    Area under the plasma concentration versus time curve of Q-GRFT collected after 13 consecutive daily intranasal applications of study product. Q-GRFT concentrations will be measured prior to the first application of study product and at 7-days, 14-days, and 28-days after the first of thirteen applications of study product.

  5. Acceptability of the Intranasal Spray [ Time Frame: Approximately 28 days ]
    The acceptability of the nasal spray use by the participant will be assessed on a 5 point Likert scale, with 1 being do not agree at all and 5 being completely agree.


Other Outcome Measures:
  1. Mean Change in Brief Smell Identification Test (BSIT) Score [ Time Frame: Approximately 14 days ]
    Mean change in Brief Smell Identification Test (BSIT) score between the score measured before the first application of study product and measured after 13 consecutive daily applications

  2. Q-GRFT Concentration from Oropharyngeal Swab Eluent Collected at 24 Hours [ Time Frame: Approximately 24 hours ]
    Q-GRFT concentration from oropharyngeal swab eluent collected 24 hours after intranasal application of a single dose of study product

  3. Q-GRFT Concentration from Nares Swab Eluent Collected at 24 Hours [ Time Frame: Approximately 24 hours ]
    Q-GRFT concentration from nares swab eluent collected 24 hours after intranasal application of a single dose of study product

  4. Q-GRFT Concentration from Oropharyngeal Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications [ Time Frame: Approximately 14 days ]
    Q-GRFT concentration from oropharyngeal swab eluent collected 24 hours after the last dose of 13 consecutive daily intranasal applications of study product.

  5. Q-GRFT Concentration from Nares Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications [ Time Frame: Approximately 14 days ]
    Q-GRFT concentration from nares swab eluent collected 24 hours after the last dose of 13 consecutive daily intranasal applications of study product.

  6. Q-GRFT Concentration from Rectal Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications [ Time Frame: Approximately 14 days ]
    Q-GRFT concentration from rectal swab eluent collected 24 hours after the last dose of 13 consecutive daily intranasal applications of study product.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Willing and able to provide written informed consent
  • In general good health as determined by the site clinician
  • Negative SARS-CoV-2 test at screening
  • Fully vaccinated for SARS-CoV-2 (does not include booster vaccination)
  • Agree to abstain from any other investigational drug studies for the duration of the study
  • Agree to abstain from nasally administered products, including over-the-counter products, for the duration of the study
  • Report use of an effective method of contraception at enrollment and intending to continue use of an effective method for the duration of study participation. Acceptable methods include:

    1. Males: Male condoms, sterilization of participant or partner, partner use of hormonal contraception or intrauterine device, identifies as a man who has sex with men exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration
    2. Females: Hormonal methods at the time of enrollment, intrauterine device inserted prior to enrollment, sterilization of participant or partner, consistent condom use of male partner for at least 28 days (reports using condoms 10 times in the last 10 acts of intercourse), identifies as a woman who has sex with women exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration.
  • Agree to participate in all study-related assessments and procedures

Exclusion Criteria:

  • Abnormal nasal or throat exam at enrollment
  • If female, pregnancy, or within 42 days of last pregnancy at screening
  • If female, breastfeeding
  • Diagnosed with SARS-CoV-2 in the past 42 days at screening
  • Diagnosed or suspected respiratory tract infection in the past 14 days at screening (including asymptomatic SARS-CoV-2)
  • Participation in an investigational drug study in past 30 days at screening
  • Any condition that, in the opinion of the Investigator would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
  • Use of any intranasal product in the 14 days prior to enrollment
  • Surgical procedure involving the nose or throat 90 days prior to enrollment
  • Any of the following laboratory abnormalities at screening:

    1. Hgb < 12g/dL (men) and < 11g/dL (women)
    2. Serum creatinine > 1.1 x upper limit of normal
    3. alanine transaminase, aspartate aminotransferase, and total bilirubin > 1.1 x upper limit of normal
  • Grade 2 or higher seasonal allergies at the time of enrollment
  • Reported use of illicit drugs

    1. Non-therapeutic injection drug use in the 12 months prior to screening
    2. Any use of methamphetamine, gamma hydroxybutyrate, cocaine or heroin in the 12 months prior to screening
  • Use of systemic prescription immunomodulatory medications within the 4 weeks prior to the enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05180500


Contacts
Layout table for location contacts
Contact: Ingrid Macio, PA-C 412-641-5455 maciis@upmc.edu
Contact: Jamie Haggerty 412-641-5378 burija@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Sharon Hillier
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Sharon L Hillier, PhD University of Pittsburgh
Layout table for additonal information
Responsible Party: Sharon Hillier, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT05180500    
Other Study ID Numbers: STUDY21100009
3P30CA047904-32S5 ( U.S. NIH Grant/Contract )
First Posted: January 6, 2022    Key Record Dates
Last Update Posted: January 6, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sharon Hillier, University of Pittsburgh:
Intranasal spray
Prophylaxis
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases